In this section:

09 April 2018

SMC Publishes Advice on Fumaric Acid Treatment for Psoriasis

On 9th April 2018, the Scottish Medicines Consortium (SMC) published its decision to recommend dimeythl fumarate (Skilarence) for the treatment of severe psoriasis in Scotland.

Dimethyl fumarate (Skilarence) is recommended to treat severe psoriasis, where people have not had adequate results from conventional systemic treatments, or cannot take them.

Some people with psoriasis may be aware of a similar treatment, known as Fumaderm or Fumaric Acid Esters. This is a German treatment that is not licensed in the UK, but has sometimes been prescribed on a case-by-case basis. Dimethyl fumarate (Skilarence) is licensed in the UK, and uses the main active ingredient from Fumaderm.

Today’s SMC recommendation, along with NICE’s positive recommendation for England and Wales last year, should make fumaric acid ester treatment more accessible to people with psoriasis in the UK.

You can read more about Skilarence here.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.